Evidence map›Paper›PMID 32065987›Full record

ArticleMolecular immunology2020

Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs.

Bal Krishan Sharma, Naresh Kumar Kakker, Sakshi Bhadouriya, Rajesh Chhabra

Abstract read
In one paragraph

Article in Molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Effects ofHeliyon · 2023
    Article
  7. Review
  8. Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. COVID-19 in pregnancy: Placental and neonatal involvement.American journal of reproductive immunology (New York, N.Y. : 1989) · 2020
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bal Krishan SharmaDepartment of Animal Husbandry, Madhya Pradesh, India.
Naresh Kumar KakkerPrincipal Scientist and Head, Department of Veterinary Microbiology, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, Haryana, 125 004, India.
Sakshi BhadouriyaDepartment of Animal Husbandry, Madhya Pradesh, India.
Rajesh ChhabraCollege Central Laboratory, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, Haryana, 125 004, India. Electronic address: rchhabra59@rediffmail.com.
Lala Lajpat Rai University of Veterinary and Animal Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Avian infectious bronchitis (IB) is an acute, highly infectious and contagious viral disease of chickens caused by avian infectious bronchitis virus (IBV) belonging to the genus Coronavirus and family Coronaviridae. It can affect all age groups of birds. The toll-like receptors (TLRs) are a major class of innate immune pattern recognition receptors that have a key role in immune response and defense against various infections.The TLRs are essential for initiation of innate immune responses and in the development of adaptive immune responses. An in ovo model was employed to study the antiviral activity of TLR ligands (Pam3CSK4, LPS and CpG ODN) on replication of IBV. It was hypothesized that optimum dose and specific timing of TLR ligands may reduce viral load of IBV in specific pathogen free (SPF) embryonated chicken eggs (ECEs). Further, the mechanism involved in the TLR-mediated antiviral response in chorioallantoic membrane (CAM) of ECEs was investigated. The ECEs of 9-11 days old were treated with different doses (high, intermediate and low) of TLR-2 (Pam3CSK4), TLR-4 (LPS) and TLR-21 (CpG ODN) ligands. In addition, to know the timing of TLR ligand treatment, six time intervals were analyzed viz. 36, 24 and 12 h prior to infection, time of infection (co-administration of TLR ligands and avian IBV) and 12 and 24 h post-IBV infection. For studying the relative expression of immuno-stimulatory genes (IFN-α, IFN-β, IFN-γ, IL-1β, iNOS and OAS) in CAM, TLR ligands were administered through intra-allantoicroute and CAM were collected at 4, 8 and 16 h post treatment. The results demonstrated that intermediate dose of all the three TLR ligands significantly reduced virus titers and used in the present study. However, the LPS reduced virus titer pre- and post-IBV infection but Pam3CSK4 and CpG ODN reduced only pre-IBV infection. Further analysis showed that TLR ligands induced IFN-γ, IL-1β and IFN stimulated genes viz. iNOS and OAS genes in CAM. The present study pointed towards the novel opportunities for rational design of LPS as immuno-stimulatory agent in chickens with reference to IBV. It may be speculated that in ovo administration of these TLR ligands may enhance resistance against viral infection in neonatal chicken and may contribute towards the development of more effective and safer vaccines including in ovo vaccines.

Indexed as

Adjuvants, ImmunologicAnimalsAntiviral AgentsAvian ProteinsChick EmbryoCoronavirus InfectionsCytokinesGene ExpressionImmunity, InnateInfectious bronchitis virusLigandsLipopeptidesLipopolysaccharidesOligodeoxyribonucleotidesPoultry DiseasesToll-Like ReceptorsAdjuvants, ImmunologicAntiviral AgentsAvian ProteinsCPG-oligonucleotideCytokinesLigandsLipopeptidesLipopolysaccharidesOligodeoxyribonucleotidesPam(3)CSK(4) peptideToll-Like ReceptorsCytokine expressionEmbryonated chicken eggsIBV replicationInfectious bronchitis virusTLR ligands

Identifiers

PMID32065987
PMCPMC7112572
OpenAlexW3006185830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.